Safety and efficacy of retreatment with a bioengineered hyaluronate for painful knee osteoarthritis
Osteoarthritis and Cartilage. 2011 Oct 1;19(10):1169-75.
Four hundred and thirty-three patients who had knee osteoarthritis (OA) entered a multicenter open-label stage of the FLEXX trial. All the patients received one injection of 2 mL IA-BioHA (a non-cross-linked, high molecular weight hyaluronan) per week for 3 weeks. About 43% of the patients reported any adverse events (AEs). Less than 5% had treatment-related AEs. Symptom improvement was maintained. The results revealed that repeated injections of IA-BioHA were safe and effective in treating knee OA.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
